Alzheimer's Therapeutics Market Size, Share & Trends Analysis Report By Product (Cholinesterase Inhibitors, Pipeline Drugs), By End Use, By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Alzheimer’s Therapeutics Market Growth & Trends
The global Alzheimer’s therapeutics market size is expected to reach USD 15.6 billion by 2030, according to a new study by Grand View Research Inc. It is expected to expand at a CAGR of 16.2% from 2022 to 2030. Government organizations are engaged in providing funds for Alzheimer's support, care, and research activities, which is projected to fuel the market growth. For instance, in March 2022, the Alzheimer's Society announced to spend around USD 3.5 billion in the coming years on dementia research to improve the care of patients.
Additionally, the Alzheimer's Association with the Alzheimer's Impact Movement (AIM) announced to utilize USD 25 million to implement the BOLD Infrastructure for Alzheimer's Act to create an effective public health substructure for patients. In addition, in September 2021, the South Texas Alzheimer's Disease Center and the Duke/University of North Carolina Alzheimer's Disease Research Center were granted USD 14.8 million over five years by the National Institute of Aging to encourage research on risk factors related to AD.
Furthermore, an increase in the incidence and cost burden of dementia associated with AD is expected to boost the market growth. According to the Alzheimer's Society, around 900,000 people are living with dementia in the United Kingdom, and it is projected to rise to 1.6 million by 2040 and the incidence of dementia will be 209,600 in the same year.
The current standard of care is limited to symptom-relieving drugs. Therefore, the approval of disease-modifying anti-amyloid therapeutics is expected to change the treatment landscape. For instance, in June 2021, the U.S. FDA granted accelerated approval to Aduhelm (aducanumab) for the treatment of patients with Alzheimer’s disease. It is a monoclonal antibody that targets cluster forms of amyloid beta present in the brains of patients and stops its formation. Other key anti-amyloid monoclonal antibodies in late-stage clinical trials include Gantenerumab (F. Hoffmann-La Roche Ltd.), Solanezumab (Eli Lilly and Company), and Lecanemab (Eisai Inc./Biogen), among others.
Alzheimer's Therapeutics Market Report Highlights
Alzheimer’s Therapeutics Market Growth & Trends
The global Alzheimer’s therapeutics market size is expected to reach USD 15.6 billion by 2030, according to a new study by Grand View Research Inc. It is expected to expand at a CAGR of 16.2% from 2022 to 2030. Government organizations are engaged in providing funds for Alzheimer's support, care, and research activities, which is projected to fuel the market growth. For instance, in March 2022, the Alzheimer's Society announced to spend around USD 3.5 billion in the coming years on dementia research to improve the care of patients.
Additionally, the Alzheimer's Association with the Alzheimer's Impact Movement (AIM) announced to utilize USD 25 million to implement the BOLD Infrastructure for Alzheimer's Act to create an effective public health substructure for patients. In addition, in September 2021, the South Texas Alzheimer's Disease Center and the Duke/University of North Carolina Alzheimer's Disease Research Center were granted USD 14.8 million over five years by the National Institute of Aging to encourage research on risk factors related to AD.
Furthermore, an increase in the incidence and cost burden of dementia associated with AD is expected to boost the market growth. According to the Alzheimer's Society, around 900,000 people are living with dementia in the United Kingdom, and it is projected to rise to 1.6 million by 2040 and the incidence of dementia will be 209,600 in the same year.
The current standard of care is limited to symptom-relieving drugs. Therefore, the approval of disease-modifying anti-amyloid therapeutics is expected to change the treatment landscape. For instance, in June 2021, the U.S. FDA granted accelerated approval to Aduhelm (aducanumab) for the treatment of patients with Alzheimer’s disease. It is a monoclonal antibody that targets cluster forms of amyloid beta present in the brains of patients and stops its formation. Other key anti-amyloid monoclonal antibodies in late-stage clinical trials include Gantenerumab (F. Hoffmann-La Roche Ltd.), Solanezumab (Eli Lilly and Company), and Lecanemab (Eisai Inc./Biogen), among others.
Alzheimer's Therapeutics Market Report Highlights
- By product, the cholinesterase inhibitors segment held the largest revenue share in 2021 as it is the current standard of care. In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc. for the treatment of patients with AD
- Pipeline drugs are anticipated to witness the fastest growth over the forecast period due to the presence of a strong product pipeline and their expected launch during the forecast period. Biogen’s product lecanemab (BAN2401), an anti-amyloid beta protofibril antibody for treating AD, is currently in phase 3 clinical trials
- The hospital pharmacy end-user segment dominated the market in 2021 owing to the high hospitalization rate. According to Alzheimer’s Association report 2022, approximately 32% of total Medicare beneficiaries with Alzheimer’s have at least one hospital discharge annually
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Gvr’s Internal Database
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Global Market: CAGR Calculation
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 ALZHEIMER’S THERAPEUTICS MARKET VARIABLES, TRENDS & SCOPE
3.1 Alzheimer’s Therapeutics Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Market Dynamics
3.4.1 Market driver analysis
3.4.1.1 Increasing prevalence of Alzheimer's disease
3.4.1.2 Presence of strong pipeline drugs for Alzheimer's disease
3.4.1.3 Introduction of innovative technologies
3.4.1.4 Increase in government funding and initiatives
3.4.1.5 Increase in Awareness programs
3.4.1.5.1 Alzheimer’s Association
3.4.1.5.2 Alzheimer’s Society of Canada
3.4.1.5.3 LatinosAgainstAlzheimer’s
3.4.1.5.4 ABRAz- Alzheimer’s Brazilian Association
3.4.2 Market restraint analysis
3.4.2.1 Presence of stringent regulatory framework
3.4.2.2 High clinical trial failures
3.5 Alzheimer’s Therapeutics Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.5.2.1 Political And Legal
3.5.2.2 Economic & Social
3.5.2.3 Technological
CHAPTER 4 ALZHEIMER’S THERAPEUTICS MARKET: SEGMENT ANALYSIS, BY PRODUCT, 2018 - 2030 (USD MILLION)
4.1 Alzheimer’s Therapeutics Market: Product Movement Analysis
4.1.1 Cholinesterase Inhibitors
4.1.1.1 Cholinesterase inhibitors market estimates and forecast, 2018 - 2030
4.1.2 N-Methyl-D-Aspartate (NMDA) Receptor Antagonist
4.1.2.1 N-Methyl-D-Aspartate (NMDA) receptor antagonist market estimates and forecast, 2018 - 2030
4.1.3 Combination Drug
4.1.3.1 Combination drug market estimates and forecast, 2018 - 2030
4.1.4 Pipeline drugs
4.1.4.1 Pipeline drugs market estimates and forecast, 2018 - 2030
CHAPTER 5 ALZHEIMER’S THERAPEUTICS MARKET: SEGMENT ANALYSIS, BY END-USER, 2018 - 2030 (USD MILLION)
5.1 Alzheimer’s Therapeutics Market: End-User Movement Analysis
5.1.1 Hospital Pharmacy
5.1.1.1 Hospital pharmacy market estimates and forecast, 2018 - 2030
5.1.2 Retail Pharmacy
5.1.2.1 Retail pharmacy market estimates and forecast, 2018 - 2030
5.1.3 e-Commerce
5.1.3.1 E-Commerce market estimates and forecast, 2018 - 2030
CHAPTER 6 ALZHEIMER’S THERAPEUTICS MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
6.1 Alzheimer’s Therapeutics Market: Regional Movement Analysis
6.1.1 North America
6.1.2 North America, SWOT Analysis
6.1.2.1 North America market estimates and forecast, 2018 - 2030
6.1.2.2 U.S.
6.1.2.2.1 U.S. market estimates and forecast, 2018 - 2030
6.1.2.3 Canada
6.1.2.3.1 Canada market estimates and forecast, 2018 - 2030
6.1.3 Europe
6.1.4 Europe, SWOT Analysis
6.1.4.1 Europe market estimates and forecast, 2018 - 2030
6.1.4.2 U.K.
6.1.4.2.1 U.K. market estimates and forecast, 2018 - 2030
6.1.4.3 Germany
6.1.4.3.1 Germany market estimates and forecast, 2018 - 2030
6.1.4.4 France
6.1.4.4.1 France market estimates and forecast, 2018 - 2030
6.1.4.5 Spain
6.1.4.5.1 Spain market estimates and forecast, 2018 - 2030
6.1.4.6 Italy
6.1.4.6.1 Italy market estimates and forecast, 2018 - 2030
6.1.5 Asia Pacific
6.1.6 Asia Pacific, SWOT Analysis
6.1.6.1 Asia Pacific market estimates and forecast, 2018 - 2030
6.1.6.2 Japan
6.1.6.2.1 Japan market estimates and forecast, 2018 - 2030
6.1.6.3 China
6.1.6.3.1 China market estimates and forecast, 2018 - 2030
6.1.6.4 India
6.1.6.4.1 India market estimates and forecast, 2018 - 2030
6.1.6.5 Australia
6.1.6.5.1 Australia market estimates and forecast, 2018 - 2030
6.1.6.6 South Korea
6.1.6.6.1 South Korea market estimates and forecast, 2018 - 2030
6.1.7 Latin America
6.1.8 Latin America, SWOT Analysis
6.1.8.1 Latin America market estimates and forecast, 2018 - 2030
6.1.8.2 Brazil
6.1.8.2.1 Brazil market estimates and forecast, 2018 - 2030
6.1.8.3 Mexico
6.1.8.3.1 Mexico market estimates and forecast, 2018 - 2030
6.1.8.4 Argentina
6.1.8.4.1 Argentina market estimates and forecast, 2018 - 2030
6.1.9 Middle East and Africa
6.1.10 Middle East & Africa, SWOT Analysis
6.1.10.1 Middle East& Africa market estimates and forecast, 2018 - 2030
6.1.10.2 South Africa
6.1.10.2.1 South Africa market estimates and forecast, 2018 - 2030
6.1.10.3 Saudi Arabia
6.1.10.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030
6.1.10.4 UAE
6.1.10.4.1 UAE market estimates and forecast, 2018 - 2030
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Recent Developments & Impact Analysis, By Key Market Participants
7.1.1 Company/Competition Categorization (Key innovators, Market leaders, Emerging Players)
7.1.1.1 Vendor landscape
7.1.1.1.1 Key company market share analysis, 2021
7.1.1.2 Public companies
7.1.1.2.1 Company market position analysis, 2021
7.1.1.2.2 Competitive dashboard analysis
7.1.1.2.3 Synergy analysis: Major deals and strategic alliances
7.2 Company Profiles
7.2.1 Eisai Co., Ltd.
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 Novartis AG
7.2.2.1 Company overview
7.2.2.2 Sandoz International GmbH
7.2.2.3 Financial performance
7.2.2.4 Product benchmarking
7.2.2.5 Strategic initiatives
7.2.3 Abbvie inc. (Allergan Plc)
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Adamas Pharmaceuticals, Inc.
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Product benchmarking
7.2.4.4 Strategic initiatives
7.2.5 H. Lundbeck A/S
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 Biogen
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 AC Immune
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 DAIICHI SANKYO COMPANY, LIMITED
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 Johnson & Johnson Services Inc.
7.2.9.1 Company overview
7.2.9.2 Janssen Global Services, LLC
7.2.9.3 Financial performance
7.2.9.4 Product benchmarking
7.2.9.5 Strategic initiatives
7.2.10 TauRx Pharmaceuticals Ltd.
7.2.10.1 Company overview
7.2.10.2 Product benchmarking
7.2.10.3 Strategic initiatives
7.2.11 F. Hoffmann La Roche Ltd.
7.2.11.1 Company overview
7.2.11.2 Product benchmarking
7.2.11.3 Strategic initiatives
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Gvr’s Internal Database
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Global Market: CAGR Calculation
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 ALZHEIMER’S THERAPEUTICS MARKET VARIABLES, TRENDS & SCOPE
3.1 Alzheimer’s Therapeutics Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Market Dynamics
3.4.1 Market driver analysis
3.4.1.1 Increasing prevalence of Alzheimer's disease
3.4.1.2 Presence of strong pipeline drugs for Alzheimer's disease
3.4.1.3 Introduction of innovative technologies
3.4.1.4 Increase in government funding and initiatives
3.4.1.5 Increase in Awareness programs
3.4.1.5.1 Alzheimer’s Association
3.4.1.5.2 Alzheimer’s Society of Canada
3.4.1.5.3 LatinosAgainstAlzheimer’s
3.4.1.5.4 ABRAz- Alzheimer’s Brazilian Association
3.4.2 Market restraint analysis
3.4.2.1 Presence of stringent regulatory framework
3.4.2.2 High clinical trial failures
3.5 Alzheimer’s Therapeutics Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.5.2.1 Political And Legal
3.5.2.2 Economic & Social
3.5.2.3 Technological
CHAPTER 4 ALZHEIMER’S THERAPEUTICS MARKET: SEGMENT ANALYSIS, BY PRODUCT, 2018 - 2030 (USD MILLION)
4.1 Alzheimer’s Therapeutics Market: Product Movement Analysis
4.1.1 Cholinesterase Inhibitors
4.1.1.1 Cholinesterase inhibitors market estimates and forecast, 2018 - 2030
4.1.2 N-Methyl-D-Aspartate (NMDA) Receptor Antagonist
4.1.2.1 N-Methyl-D-Aspartate (NMDA) receptor antagonist market estimates and forecast, 2018 - 2030
4.1.3 Combination Drug
4.1.3.1 Combination drug market estimates and forecast, 2018 - 2030
4.1.4 Pipeline drugs
4.1.4.1 Pipeline drugs market estimates and forecast, 2018 - 2030
CHAPTER 5 ALZHEIMER’S THERAPEUTICS MARKET: SEGMENT ANALYSIS, BY END-USER, 2018 - 2030 (USD MILLION)
5.1 Alzheimer’s Therapeutics Market: End-User Movement Analysis
5.1.1 Hospital Pharmacy
5.1.1.1 Hospital pharmacy market estimates and forecast, 2018 - 2030
5.1.2 Retail Pharmacy
5.1.2.1 Retail pharmacy market estimates and forecast, 2018 - 2030
5.1.3 e-Commerce
5.1.3.1 E-Commerce market estimates and forecast, 2018 - 2030
CHAPTER 6 ALZHEIMER’S THERAPEUTICS MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
6.1 Alzheimer’s Therapeutics Market: Regional Movement Analysis
6.1.1 North America
6.1.2 North America, SWOT Analysis
6.1.2.1 North America market estimates and forecast, 2018 - 2030
6.1.2.2 U.S.
6.1.2.2.1 U.S. market estimates and forecast, 2018 - 2030
6.1.2.3 Canada
6.1.2.3.1 Canada market estimates and forecast, 2018 - 2030
6.1.3 Europe
6.1.4 Europe, SWOT Analysis
6.1.4.1 Europe market estimates and forecast, 2018 - 2030
6.1.4.2 U.K.
6.1.4.2.1 U.K. market estimates and forecast, 2018 - 2030
6.1.4.3 Germany
6.1.4.3.1 Germany market estimates and forecast, 2018 - 2030
6.1.4.4 France
6.1.4.4.1 France market estimates and forecast, 2018 - 2030
6.1.4.5 Spain
6.1.4.5.1 Spain market estimates and forecast, 2018 - 2030
6.1.4.6 Italy
6.1.4.6.1 Italy market estimates and forecast, 2018 - 2030
6.1.5 Asia Pacific
6.1.6 Asia Pacific, SWOT Analysis
6.1.6.1 Asia Pacific market estimates and forecast, 2018 - 2030
6.1.6.2 Japan
6.1.6.2.1 Japan market estimates and forecast, 2018 - 2030
6.1.6.3 China
6.1.6.3.1 China market estimates and forecast, 2018 - 2030
6.1.6.4 India
6.1.6.4.1 India market estimates and forecast, 2018 - 2030
6.1.6.5 Australia
6.1.6.5.1 Australia market estimates and forecast, 2018 - 2030
6.1.6.6 South Korea
6.1.6.6.1 South Korea market estimates and forecast, 2018 - 2030
6.1.7 Latin America
6.1.8 Latin America, SWOT Analysis
6.1.8.1 Latin America market estimates and forecast, 2018 - 2030
6.1.8.2 Brazil
6.1.8.2.1 Brazil market estimates and forecast, 2018 - 2030
6.1.8.3 Mexico
6.1.8.3.1 Mexico market estimates and forecast, 2018 - 2030
6.1.8.4 Argentina
6.1.8.4.1 Argentina market estimates and forecast, 2018 - 2030
6.1.9 Middle East and Africa
6.1.10 Middle East & Africa, SWOT Analysis
6.1.10.1 Middle East& Africa market estimates and forecast, 2018 - 2030
6.1.10.2 South Africa
6.1.10.2.1 South Africa market estimates and forecast, 2018 - 2030
6.1.10.3 Saudi Arabia
6.1.10.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030
6.1.10.4 UAE
6.1.10.4.1 UAE market estimates and forecast, 2018 - 2030
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Recent Developments & Impact Analysis, By Key Market Participants
7.1.1 Company/Competition Categorization (Key innovators, Market leaders, Emerging Players)
7.1.1.1 Vendor landscape
7.1.1.1.1 Key company market share analysis, 2021
7.1.1.2 Public companies
7.1.1.2.1 Company market position analysis, 2021
7.1.1.2.2 Competitive dashboard analysis
7.1.1.2.3 Synergy analysis: Major deals and strategic alliances
7.2 Company Profiles
7.2.1 Eisai Co., Ltd.
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 Novartis AG
7.2.2.1 Company overview
7.2.2.2 Sandoz International GmbH
7.2.2.3 Financial performance
7.2.2.4 Product benchmarking
7.2.2.5 Strategic initiatives
7.2.3 Abbvie inc. (Allergan Plc)
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Adamas Pharmaceuticals, Inc.
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Product benchmarking
7.2.4.4 Strategic initiatives
7.2.5 H. Lundbeck A/S
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 Biogen
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 AC Immune
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 DAIICHI SANKYO COMPANY, LIMITED
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 Johnson & Johnson Services Inc.
7.2.9.1 Company overview
7.2.9.2 Janssen Global Services, LLC
7.2.9.3 Financial performance
7.2.9.4 Product benchmarking
7.2.9.5 Strategic initiatives
7.2.10 TauRx Pharmaceuticals Ltd.
7.2.10.1 Company overview
7.2.10.2 Product benchmarking
7.2.10.3 Strategic initiatives
7.2.11 F. Hoffmann La Roche Ltd.
7.2.11.1 Company overview
7.2.11.2 Product benchmarking
7.2.11.3 Strategic initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Regulatory and reimbursement framework
Table 4 North America Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 5 North America Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 7 U.S. Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 8 U.S. Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 9 Canada Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 10 Canada Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 11 Europe Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 12 Europe Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 13 U.K. Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 14 U.K. Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 15 Germany Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 16 Germany Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 17 France Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 18 France Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 19 Italy Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 20 Italy Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 21 Spain Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 22 Spain Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 23 Asia Pacific Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 24 Asia Pacific Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 25 Japan Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 26 Japan Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 27 China Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 28 China Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 29 India Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 30 India Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 31 Australia Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 32 Australia Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 33 South Korea Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 34 South Korea Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 35 Latin America Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 36 Latin America Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 37 Brazil Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 38 Brazil Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 39 Mexico Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 40 Mexico Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 41 Argentina Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 42 Argentina Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 43 Middle East & Africa Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 44 Middle East & Africa Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 45 South Africa Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 46 South Africa Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 47 Saudi Arabia Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 48 Saudi Arabia Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 49 UAE Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 50 UAE Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Regulatory and reimbursement framework
Table 4 North America Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 5 North America Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 7 U.S. Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 8 U.S. Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 9 Canada Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 10 Canada Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 11 Europe Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 12 Europe Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 13 U.K. Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 14 U.K. Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 15 Germany Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 16 Germany Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 17 France Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 18 France Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 19 Italy Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 20 Italy Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 21 Spain Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 22 Spain Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 23 Asia Pacific Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 24 Asia Pacific Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 25 Japan Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 26 Japan Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 27 China Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 28 China Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 29 India Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 30 India Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 31 Australia Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 32 Australia Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 33 South Korea Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 34 South Korea Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 35 Latin America Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 36 Latin America Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 37 Brazil Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 38 Brazil Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 39 Mexico Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 40 Mexico Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 41 Argentina Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 42 Argentina Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 43 Middle East & Africa Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 44 Middle East & Africa Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 45 South Africa Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 46 South Africa Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 47 Saudi Arabia Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 48 Saudi Arabia Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
Table 49 UAE Alzheimer’s Therapeutics Market, By Product, 2018 - 2030 (USD Million)
Table 50 UAE Alzheimer’s Therapeutics Market, By End-User, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Alzheimer’s therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Alzheimer’s therapeutics market snapshot (2021)
Fig. 10 Penetration & growth prospect mapping
Fig. 11 Market driver impact analysis (Current & future impact)
Fig. 12 Prevalence of Alzheimer’s disease by age group
Fig. 13 Pipeline drugs for Alzheimer’s treatment, by development phase
Fig. 14 Market restraint impact analysis (Current & future impact)
Fig. 15 Porter’s five forces analysis
Fig. 16 Alzheimer’s therapeutics market: Product outlook and key takeaways
Fig. 17 Alzheimer’s therapeutics market: Product movement analysis
Fig. 18 Cholinesterase inhibitors market estimates and forecast, 2018 - 2030
Fig. 19 N-methyl-D-aspartate receptor antagonist market estimates and forecast, 2018 - 2030
Fig. 20 Combination drug market estimates and forecast, 2018 - 2030
Fig. 21 Pipeline drugs market estimates and forecast, 2018 - 2030
Fig. 22 Alzheimer’s therapeutics market: End-user outlook and key takeaways
Fig. 23 Alzheimer’s therapeutics market: End-user movement analysis
Fig. 24 Hospital pharmacy market estimates and forecast, 2018 - 2030
Fig. 25 Retail pharmacy market estimates and forecast, 2018 - 2030
Fig. 26 E-commerce market estimates and forecast, 2018 - 2030
Fig. 27 Alzheimer’s therapeutics market: Regional outlook and key takeaways
Fig. 28 Alzheimer’s therapeutics market: Regional movement analysis
Fig. 29 North America
Fig. 30 North America, SWOT
Fig. 31 North America market estimates and forecast, 2018 - 2030
Fig. 32 U.S.
Fig. 33 U.S. market estimates and forecast, 2018 - 2030
Fig. 34 Canada
Fig. 35 Canada market estimates and forecast, 2018 - 2030
Fig. 36 Europe
Fig. 37 Europe, SWOT
Fig. 38 Europe market estimates and forecast, 2018 - 2030
Fig. 39 U.K.
Fig. 40 U.K. market estimates and forecast, 2018 - 2030
Fig. 41 Germany
Fig. 42 Germany market estimates and forecast, 2018 - 2030
Fig. 43 France
Fig. 44 France market estimates and forecast, 2018 - 2030
Fig. 45 Spain
Fig. 46 Spain market estimates and forecast, 2018 - 2030
Fig. 47 Italy
Fig. 48 Italy market estimates and forecast, 2018 - 2030
Fig. 49 Asia Pacific
Fig. 50 Asia Pacific, SWOT
Fig. 51 Asia Pacific market estimates and forecast, 2018 - 2030
Fig. 52 Japan
Fig. 53 Japan market estimates and forecast, 2018 - 2030
Fig. 54 China
Fig. 55 China market estimates and forecast, 2018 - 2030
Fig. 56 India
Fig. 57 India market estimates and forecast, 2018 - 2030
Fig. 58 Australia
Fig. 59 Australia market estimates and forecast, 2018 - 2030
Fig. 60 South Korea
Fig. 61 South Korea market estimates and forecast, 2018 - 2030
Fig. 62 Latin America
Fig. 63 Latin America, SWOT
Fig. 64 Latin America. market estimates and forecast, 2018 - 2030
Fig. 65 Brazil
Fig. 66 Brazil market estimates and forecast, 2018 - 2030
Fig. 67 Mexico
Fig. 68 Mexico market estimates and forecast, 2018 - 2030
Fig. 69 Argentina
Fig. 70 Argentina market estimates and forecast, 2018 - 2030
Fig. 71 Middle East & Africa
Fig. 72 Middle East & Africa, SWOT
Fig. 73 MEA market estimates and forecast, 2018 - 2030
Fig. 74 South Africa
Fig. 75 South Africa market estimates and forecast, 2018 - 2030
Fig. 76 Saudi Arabia
Fig. 77 Saudi Arabia market estimates and forecast, 2018 - 2030
Fig. 78 UAE
Fig. 79 UAE market estimates and forecast, 2018 - 2030
Fig. 80 Company/Competition categorization (key innovators, market leaders, emerging players)
Fig. 81 Company Market Share Analysis
Fig. 82 Company Market Position Analysis, 2021
Fig. 83 Competitive Dashboard Analysis
Fig. 1 Alzheimer’s therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Alzheimer’s therapeutics market snapshot (2021)
Fig. 10 Penetration & growth prospect mapping
Fig. 11 Market driver impact analysis (Current & future impact)
Fig. 12 Prevalence of Alzheimer’s disease by age group
Fig. 13 Pipeline drugs for Alzheimer’s treatment, by development phase
Fig. 14 Market restraint impact analysis (Current & future impact)
Fig. 15 Porter’s five forces analysis
Fig. 16 Alzheimer’s therapeutics market: Product outlook and key takeaways
Fig. 17 Alzheimer’s therapeutics market: Product movement analysis
Fig. 18 Cholinesterase inhibitors market estimates and forecast, 2018 - 2030
Fig. 19 N-methyl-D-aspartate receptor antagonist market estimates and forecast, 2018 - 2030
Fig. 20 Combination drug market estimates and forecast, 2018 - 2030
Fig. 21 Pipeline drugs market estimates and forecast, 2018 - 2030
Fig. 22 Alzheimer’s therapeutics market: End-user outlook and key takeaways
Fig. 23 Alzheimer’s therapeutics market: End-user movement analysis
Fig. 24 Hospital pharmacy market estimates and forecast, 2018 - 2030
Fig. 25 Retail pharmacy market estimates and forecast, 2018 - 2030
Fig. 26 E-commerce market estimates and forecast, 2018 - 2030
Fig. 27 Alzheimer’s therapeutics market: Regional outlook and key takeaways
Fig. 28 Alzheimer’s therapeutics market: Regional movement analysis
Fig. 29 North America
Fig. 30 North America, SWOT
Fig. 31 North America market estimates and forecast, 2018 - 2030
Fig. 32 U.S.
Fig. 33 U.S. market estimates and forecast, 2018 - 2030
Fig. 34 Canada
Fig. 35 Canada market estimates and forecast, 2018 - 2030
Fig. 36 Europe
Fig. 37 Europe, SWOT
Fig. 38 Europe market estimates and forecast, 2018 - 2030
Fig. 39 U.K.
Fig. 40 U.K. market estimates and forecast, 2018 - 2030
Fig. 41 Germany
Fig. 42 Germany market estimates and forecast, 2018 - 2030
Fig. 43 France
Fig. 44 France market estimates and forecast, 2018 - 2030
Fig. 45 Spain
Fig. 46 Spain market estimates and forecast, 2018 - 2030
Fig. 47 Italy
Fig. 48 Italy market estimates and forecast, 2018 - 2030
Fig. 49 Asia Pacific
Fig. 50 Asia Pacific, SWOT
Fig. 51 Asia Pacific market estimates and forecast, 2018 - 2030
Fig. 52 Japan
Fig. 53 Japan market estimates and forecast, 2018 - 2030
Fig. 54 China
Fig. 55 China market estimates and forecast, 2018 - 2030
Fig. 56 India
Fig. 57 India market estimates and forecast, 2018 - 2030
Fig. 58 Australia
Fig. 59 Australia market estimates and forecast, 2018 - 2030
Fig. 60 South Korea
Fig. 61 South Korea market estimates and forecast, 2018 - 2030
Fig. 62 Latin America
Fig. 63 Latin America, SWOT
Fig. 64 Latin America. market estimates and forecast, 2018 - 2030
Fig. 65 Brazil
Fig. 66 Brazil market estimates and forecast, 2018 - 2030
Fig. 67 Mexico
Fig. 68 Mexico market estimates and forecast, 2018 - 2030
Fig. 69 Argentina
Fig. 70 Argentina market estimates and forecast, 2018 - 2030
Fig. 71 Middle East & Africa
Fig. 72 Middle East & Africa, SWOT
Fig. 73 MEA market estimates and forecast, 2018 - 2030
Fig. 74 South Africa
Fig. 75 South Africa market estimates and forecast, 2018 - 2030
Fig. 76 Saudi Arabia
Fig. 77 Saudi Arabia market estimates and forecast, 2018 - 2030
Fig. 78 UAE
Fig. 79 UAE market estimates and forecast, 2018 - 2030
Fig. 80 Company/Competition categorization (key innovators, market leaders, emerging players)
Fig. 81 Company Market Share Analysis
Fig. 82 Company Market Position Analysis, 2021
Fig. 83 Competitive Dashboard Analysis
